Category: Resources
-
Investigative therapy for melanoma promising
Combination of chemotherapy and immunotherapy of adoptive cell transfer with tumor infiltrating lymphocytes, followed by interleukin-2, is labor-intensive but a feasible therapy with a high response rate in treated patients.
-
Relative Roles of Targeted Therapies and Immunotherapies in Melanoma
Anti PD1. Dr. Mario Sznol is Professor of Medicine at the Yale School of Medicine and the clinical Research Program Leader of the Yale Cancer Center’s Melanoma Program. In this interview, Dr. Sznol shares unique insights into these two treatment approaches, including how they compare and how they might be combined
-
Dr. Kris on the Combination of Targeted Therapies
Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses a phase I/II trial examining the combination of two investigational targeted therapies for patients with BRAF-mutated melanoma. Kris believes this trial showcases the changes taking place in cancer care, as a result of the molecular revolution. Traditionally, adding two…
-
Melanoma Drug Pipeline Update 2012
Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.There are today 242 companies plus partners developing 273 drugs targeting melanoma in development. In addition, there are…
-
Inflammation Induces Melanoma’s ‘Invisibility’ to T-cell Immunotherapy
(ChemotherapyAdvisor) – Inflammation can trigger reversible losses of antigens from melanoma cell surfaces, cloaking tumors from T-cell detection, report authors of a study published in the journal Nature. The finding might help explain melanoma resistance and relapse after initially-effective immunotherapy, the authors reported. “Adaptive cell transfer therapies (ACTs) using cytotoxic T-cells that target melanocytic antigens…
-
Targeted Therapy: Its Status and Promise in Selected Solid Tumors Part I: Areas of Major Impact
ABSTRACT: “Targeted therapy” is becoming the centerpiece of current therapeutic strategies, and is often mentioned as the desirable direction for future progress. Why and how it is replacing past approaches in the management of solid tumors is the subject of this two-part overview. Here, in Part I, we describe areas where major inroads were initially…
-
Practical Approaches to Metastatic Melanoma in the Molecular Era
Every year more than 53,000 people in the United States are diagnosed with melanoma, making it the fastest growing cancer both in the United States and worldwide, especially among young adults between the ages of 20 and 30 years. While melanoma is treatable when detected in the early stages, it causes almost 8,000 deaths annually.…
-
Dabrafenib Shows Efficancy in Metastatic Melanoma
A summary of the phase III BREAK-3 trial comparing the BRAF inhibitor dabrafenib with the chemotherapy agent dacarbazine (DTIC). Patients taking dabrafenib had an improved progression-free survival (PFS) of 2.4 months compared with patients receiving chemotherapy. Read more…
-
Doctors to Watch
Antoni Ribas UCLA melanoma – Dr. Ribas is a physician-scientist conducting laboratory and clinical research focused in malignant melanoma. His research includes: laboratory and clinical translational research in adoptive cell transfer therapy with T-cell receptor (TCR) engineered lymphocytes understanding the antitumor activity of CTLA4-blocking antibodies molecular imaging and advanced immune monitoring for the study of…
-
Hospitals To Consider
MD Anderson Melanoma – The Ben Love/El Paso Corporation Melanoma and Skin Center is committed to fighting every type and stage of skin cancer. MD Anderson’s goal is to give each patient personalized care that provides the most advanced treatment with the least impact on the body for: Melanoma of the skin (ie, cutaneous melanoma)…